Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797693 | 0.85 | CA12 (0.46) | TSHRALDH1A1NLRP3CASP1MEN1 | |
| SCHEMBL5972758 | 0.85 | TSHR (0.48) | TSHRALDH1A1NLRP3MEN1NPC1 | |
| SCHEMBL312971 | 0.84 | POLB (0.48) | TSHRALDH1A1NLRP3MEN1KMT2A | |
| SCHEMBL3224732 | 0.84 | NLRP3 (0.44) | TSHRALDH1A1NLRP3CASP1NPC1 | |
| SCHEMBL7529144 | 0.84 | TSHR (0.44) | TSHRALDH1A1NLRP3CASP1MEN1 | |
| SCHEMBL16796779 | 0.84 | CYP4F2 (0.45) | NLRP3CASP1CYP4F2CYP4A11 | |
| SCHEMBL8771003 | 0.84 | CASP1 (0.57) | TSHRALDH1A1NLRP3CASP1MEN1 | |
| SCHEMBL2320013 | 0.83 | ALDH1A1 (0.47) | TSHRALDH1A1NLRP3MEN1NPC1 | |
| SCHEMBL12499810 | 0.83 | ALDH1A1 (0.47) | TSHRALDH1A1NLRP3MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL2319627 | 0.82 | ALDH1A1 (0.46) | TSHRALDH1A1NLRP3MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | TSHR 3177/4885ALDH1A1 1252/4885NLRP3 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.